ACTRIMSForum 2016

18-20 February 2016
Hyatt Regency, New Orleans
601 Loyola Ave, New Orleans, Louisiana, USA 70113

Theme: Progressive MS: From Bench to Bedside and Back

Thursday, February 18, 2016

8:00 am-7:00 pm Registration and Information Desk Open
2:00 pm-2:10 pm Opening Address
Suhayl Dhib-Jalbut (Rutgers University)
2:10 pm-4:10 pm

SESSION 1 Emerging Concepts in MS
Highlighting cutting edge studies that inform our understanding of the pathogenic mechanisms in MS,introduce novel measures to capture disease activity,and advance treatment options for affected individuals. (This Session will be comprised of platform presentations by junior faculty selected from highest-rated submitted abstracts.)

Chairs: Jack Antel (McGill University) and Tiffany Braley (University of Michigan)

2:10 pm-2:30 pm Talk 1: Immunomodulatory therapy slows accumulation of disability in moderately advanced multiple sclerosis
Nathaniel Lizak (University of Melbourne)
2:30 pm-2:50 pm Talk 2: Modeling Leptomeningeal Inflammation in EAE - insights into pathophysiology and a new method to screen potential therapies for MS
Pavan Bhargava (Johns Hopkins University)
2:50 pm-3:10 pm  Talk 3: Failure of early repair in MS lesions with persistent paramagnetic RIM at 7T
Martina Absinta (National Institutes of Health)
3:10 pm-3:30 pm  Talk 4: Acute effects of treadmill walking exercise on inhibitory control in MS: do exercise intensity and thermosensitivity matter?
Brian Sandroff (Kessler Foundation)

3:30 pm-3:50 pm

Talk 5: Antibodies to the RNA binding protein hnRNP A1 contribute to neurodegeneration indicative of 'dying back' axonopathy
Hannah Salapa (The University of Tennessee Health Science Center)
3:50 pm- 4:10 pm  Talk 6: Combination of biologically related biomarkers quantifies infiltration of CNS tissue by immune cells in progressive
Mika Komori (National Institutes of Health)
4:10 pm-4:30 pm Break
4:30 pm-5:45 pm

SATELLITE SYMPOSIUM 1 - Implementing B-Cell Based Therapeutic Science to Improve Outcomes for Your Patients with Multiple Sclerosis: What Every Neurologist Needs to Know

Chair: Fred D. Lublin (Mt. Sinai Hospital)

6:00 pm-7:00 pm Kenneth P. Johnson Memorial Lecture
Dr. Jerry S. Wolinsky (The University of Texas Health Science Center of Houston)
7:00 pm-9:00 pm Opening Networking Event 

Friday, February 19, 2016

6:30 am - 6:30 pm Registration and Information Desk Open
7:00 am-8:15 am

SATELLITE SYMPOSIUM 2 - Disrupting Disease Worsening in Patients with MS: How Can We Harness the Full Potential of Available Disease-Modifying Therapies?

Chair: Aaron Boster (OhioHealth Neurological Physicians)

8:30 am-10:15 am

SESSION 2– Lessons from the Bench: Pathogenic Mechanisms in Progressive MS
The Contributions of Inflammation Versus Neurodegeneration to CNS Damageand Clinical Disability

Chairs: Benjamin Segal (University of Michigan) and Greg Wu (Washington University in St. Louis)

8:30 am-8:35 am Opening Comments by Session Chair
8:35 am-9:00 am Talk 1: Axonopathy, Mitochondrial Abnormalities and Disability MS
Dr. Don Mahad (University of Edinburg)
9:00 am-9:25 am Talk 2: Cytokine Dysregulation and Neuroinflammation in PPMS and SPMS
Dr. David Irani (University of Michigan) 
9:25 am-9:50 am Talk 3: Lessons from the Genome Wide Association Studies: Immune and CNS-related Susceptibility Alleles
Dr. Philip De Jager (Harvard Medical School)
9:50 am-10:15 am Panel Discussion
10:15 am-10:45 am Break
10:45 am-12:30 am

SESSION 3– Highlights: Neuropathological Studies and Clinical Trials
The Heterogeneity of Progressive MS: Implications for Trial Design and Customized Therapy

Chairs: Samuel Ludwin (Queen's University & Montreal Neurological Institute) and Jeffrey Cohen (Cleveland Clinic)

10:45 am-10:50 am Opening Comments by Session Chair
10:50 am-11:15 am Talk 1: The Histopathology of RRMS Versus Progressive MS: Distinctive and Overlapping Features
Dr. Wayne G.R. Moore (University of British Columbia)
11:15 am-11:40 am Talk 2: The Pathology of Progress in Multiple Sclerosis 
Dr. Claudia Luchinetti (Mayo Clinic)
11:40 am-12:05 pm Talk 3: Intrathecal Rituximab in Progressive MS 
Dr. Peter Calabresi (Johns Hopkins University)
12:05 pm-12:30 pm Panel Discussion
12:30 pm-2:00 pm Poster Session and Lunch
2:00 pm-3:45 pm

SESSION 4– Measuring Disease Progression in MS
Biological and Radiological Markers of Disease Progression –CapturingElusive Targets

Chairs:  Fiona Costello (University of Calgary) and Shiv Saida (Johns Hopkins)

2:00 pm-2:05 pm Opening Comments by Session Chair
2:05 pm-2:30 pm Talk 1: Capturing Primary Neuronal Loss in the Afferent Visual Pathway
Dr. Ari Green (University of California San Francisco)
2:30 pm-2:55 pm Talk 2: MRI as an Outcome Measure in Progressive MS
Dr. Daniel Reich (National Institutes of Health)
2:55 pm-3:20 pm Talk 3: Micro RNA Biomarkers in Early and Later Stage 
Dr. Konstantin Balashov (Rutgers University)
3:20 pm-3:45 pm Panel Discussion
3:45 pm-4:00 pm Break
4:00 pm-4:30 pm

LATE BREAKING SESSION: Cutting Edge Developments in MS Research

Chairs: Benjamin Segal (University of Michigan) and Fiona Costello (University of Calgary)

4:00 pm- 4:10 pm  Talk 1: Can the degree of meningeal inflammation and cortical pathology be used to stratify early progessive MS patients? 
Roberta Magliozzi (Imperial College London)
4:10 pm- 4:20 pm Talk 2: Ovarian age is associated with gray matter volume and disability in women with MS independent of chronological age and disease duration
Jennifer S. Graves (University of California, San Francisco)
4:20 pm- 4:30 pm  Talk 3: Efficacy of ocrelizumab in patients with PPMS with and without T1 gadolinium-enhancing lesions at baseline in a Phase III, placebo-controlled trial
Jerry Wolinsky (The University of Texas Health Science Center of Houston)
4:30 pm-6:30 pm Poster Session 2 and Cocktail Reception
7:00 pm-10:00 pm

Networking Dinner 

Moderator: Jeffrey A. Cohen (Cleveland Clinic)

Saturday, February 20, 2016

7:00 am-8:15 am ACTRIMS Board of Directors Breakfast Meeting - by invitation only
8:00 am-1:00 pm Registration and Information Desk Open
8:30 am-10:15 am

SESSION 5 The Treatment Pipeline: New Experimental Therapies
Milestones: Clinical Trials in Progressive Multiple Sclerosis

Chairs: Mark Freedman (Ottawa Hospital Research Institute) and John Rinker, III (University of Alabama) 

8:30 am-8:35 am Opening Comments by Session Chair
8:35 am-9:00 am Talk 1: Breaking News on Results of Recently Completed Trials
Dr. Fred Lublin (Mt. Sinai)
9:00 am-9:25 am Talk 2: Recent Studies Funded by the PMSA
Dr. Tim Coetzee (National MS Society)
9:25 am-9:50 am Talk 3: Stem Cell Transplantation
Dr. Andrew Goodman (University of Rochester)
9:50 am-10:15 am Panel Discussion
10:15 am-10:45 am Break
10:50 am-12:35 am

SESSION 6 Meeting Conclusions and Future Directions

Chairs: Suhayl Dhib-Jalbut (Rutgers University) and Rhonda Voskuhl (UCLA)

10:50 am-10:55 am Opening Comments by Session Chair
10:55 am-11:20 am Summary 1: Session 1 - Emerging Concepts in MS
Michael Levin (University of Tennessee)
11:20 am-11:45 am Summary 2: Session 2 - Lessons from the Bench
Dr. Olaf Stuve (University of Texas - Southwestern)
11:45 am-12:10 pm Summary 3: Session 4 - Capturing Disease Activity
Dr. E. Ann Yeh (University of Toronto)
12:10 pm-12:35 pm Summary 4: Session 5 - Experimental Therapeutics
Dr. Myla Goldman (UVA Neuroscience Center)
12:35 pm-1:00 pm Closing Remarks and Award Presentations